Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BOSTON BIO SYSTEMS LTD.

NSE : NABSE : 531458ISIN CODE : INE109B01019Industry : Medical Equipment/Supplies/AccessoriesHouse : Private

BSE6.970.13 (+1.9 %)

PREV CLOSE ( ) 6.84

OPEN PRICE ( ) 6.97

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 100

TODAY'S LOW / HIGH ( )6.97 6.97

52 WK LOW / HIGH ( ) 6.5322

NSE

This Company is not listed in NSE

Select year

(Rs.in Million)

Particulars

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Profit Before Tax

-1.41

-0.02

Adjustment

Changes In working Capital

1.41

0.01

-0.01

Cash Flow after changes in Working Capital

-0.01

-0.02

Cash Flow from Operating Activities

-0.01

-0.02

Cash Flow from Investing Activities

Cash Flow from Financing Activities

Net Cash Inflow / Outflow

-0.01

-0.02

Opening Cash & Cash Equivalents

0.53

0.54

0.55

0.56

0.58

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

0.53

0.54

0.55

0.56